查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589053

結合疫苗市場：按類型、適應症、病原體類型、最終用戶分類 - 2025-2030 年全球預測

Conjugate Vaccine Market by Type (Monovalent, Multivalent), Indication (Diphtheria & Pertussis, Influenza, Meningococcal), Pathogen Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年結合疫苗市場規模為396.7億美元，預計2024年將達439.2億美元，複合年成長率為10.81%，2030年將達814.2億美元。

結合疫苗對於預防腦膜炎、肺炎和 b 型流感嗜血桿菌 (Hib) 等侵襲性疾病至關重要，透過將多醣抗原與蛋白質載體結合，可以提高免疫抗原性，尤其是在幼兒中。它的需求源自於其產生持久免疫反應和群體免疫、降低疾病發生率的能力。典型應用包括針對容易罹患某些感染疾病的嬰幼兒、幼兒和成人的疫苗接種計劃。最終用途包括醫院、診所、公共衛生機構、研究組織等。關鍵的成長要素包括對疫苗可預防疾病的認知提高、政府免疫措施以及疫苗開發的技術進步。醫療保健基礎設施的持續投資以及更嚴格的醫療政策對兒科疫苗的需求增加為市場提供了支撐。 COVID-19 大流行也凸顯了疫苗的重要性，並提高了市場對預防性醫療保健的整體關注。疫苗接種率低的地區也有新的商機，凸顯市場拓展潛力。研發策略聯盟可以推動創新並最大限度地提高市場滲透率。然而，對疫苗開發的猶豫、供應鏈中斷以及疫苗開發成本上升等限制因素可能會阻礙成長。嚴格的監管環境需要廣泛的臨床評估，這帶來了額外的挑戰。創新可能會在開發耐熱疫苗、新型佐劑系統以及同時針對多種病原體的組合疫苗方面取得進展。探索新的結合機制和替代載體蛋白可以提高功效並擴大保護範圍。該市場仍然競爭激烈，重點是生物技術公司、全球衛生組織和政府機構之間的合作，以擴大疫苗的供應。透過在疫苗設計中利用人工智慧和機器學習等最尖端科技，公司可以最佳化疫苗效率並應對新出現的病原體挑戰，從而成為該領域的領導者。

主要市場統計
基準年[2023] 396.7億美元
預測年份 [2024] 439.2億美元
預測年份 [2030] 814.2億美元
複合年成長率（%） 10.81%

市場動態：快速發展的結合疫苗市場的關鍵市場洞察

供給和需求的動態交互作用正在改變結合疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 感染疾病和免疫抑制盛行率增加
    • 癌症治療疫苗的採用增加
    • 世衛組織增加疫苗接種推廣計劃
  • 市場限制因素
    • 偏遠地區疫苗取得困難
  • 市場機會
    • 政府努力提高人們對感染疾病的認知
    • 新型結合疫苗生產技術的進展
  • 市場挑戰
    • 結合疫苗生產程序的複雜性

波特五力：駕馭結合疫苗市場的策略工具

波特的五力框架是了解結合疫苗市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對結合疫苗市場的影響

外部宏觀環境因素在塑造結合疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解聯合疫苗市場的競爭狀況

對結合疫苗市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣結合疫苗市場供應商績效評估

FPNV定位矩陣是評估結合疫苗市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了結合疫苗市場的成功之路

結合疫苗市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病增加和免疫抑制
      • 癌症治療疫苗的採用增加
      • 世衛組織增加疫苗接種推廣計劃
    • 抑制因素
      • 偏遠地區獲得疫苗的機會很少
    • 機會
      • 政府努力提高人們對感染疾病的認知
      • 新型結合疫苗生產技術進展
    • 任務
      • 結合疫苗生產程序的複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章結合疫苗市場：依類型

  • 單價
  • 多效價的

第7章 結合疫苗市場適應症

  • 白喉和百日咳
  • 流感
  • 腦膜炎奈瑟菌
  • 肺炎球菌

第8章以病原體類型分類的結合疫苗市場

  • 細菌結合疫苗
  • 聯合結合疫苗
  • 病毒結合疫苗

第9章結合疫苗市場：依最終用戶分類

  • 成人
  • 孩子們

第10章美洲結合疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太結合疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章：歐洲、中東和非洲結合疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Bavarian Nordic
  • Bharat Biotech Ltd.
  • Bio-Med Limited
  • Biological E. Limited
  • Biological E. Ltd
  • CSL Limited
  • GlaxoSmithKline, plc.
  • Merck and Company
  • Novartis AG
  • Nuron Biotech Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur US, LLC
  • Serum Institute of India Pvt. Ltd.
  • Taj Pharmaceuticals Limited
  • Vaxcyte, Inc.
Product Code: MRR-433AB1DC2901

The Conjugate Vaccine Market was valued at USD 39.67 billion in 2023, expected to reach USD 43.92 billion in 2024, and is projected to grow at a CAGR of 10.81%, to USD 81.42 billion by 2030.

Conjugate vaccines are critical in preventing invasive diseases like meningitis, pneumonia, and Haemophilus influenzae type b (Hib) by linking polysaccharide antigens to protein carriers, enhancing immunogenicity, especially in young children. Their necessity stems from their ability to generate long-lasting immune responses and herd immunity, reducing disease incidence. Applications mainly include immunization programs targeting infants, young children, and adults with higher susceptibility to certain infectious diseases. End-use scope encompasses hospitals, clinics, public health agencies, and research institutions. Key growth influencers include heightened awareness of vaccine-preventable diseases, government immunization initiatives, and technological advancements in vaccine development. The market is buoyed by persistent investments in healthcare infrastructure and rising demand for pediatric vaccines due to stricter healthcare policies. The COVID-19 pandemic has also underscored the significance of vaccines, broadening the overall market focus on preventive healthcare. Emerging opportunities lie in geographical regions with low immunization coverage, highlighting the potential for expanding market footprints. Strategic collaborations in research and development sectors can propel technological innovations, maximizing market access. However, limitations such as vaccine hesitancy, supply chain disruptions, and high costs of vaccine development could impede growth. Stringent regulatory landscapes requiring extensive clinical evaluations pose additional challenges. Innovation can thrive in the development of thermostable vaccines, novel adjuvant systems, and combination vaccines that address multiple pathogens simultaneously. Exploring new mechanisms of conjugation and alternative carrier proteins can enhance efficacy and broaden protective scope. The nature of the conjugate vaccine market remains highly competitive, with a focus on partnerships between biotech firms, global health bodies, and governmental agencies to expand vaccine accessibility. By leveraging cutting-edge technologies like AI and machine learning in vaccine design, companies can optimize vaccine efficiency and target new pathogenic challenges, positioning themselves as leaders in the field.

KEY MARKET STATISTICS
Base Year [2023] USD 39.67 billion
Estimated Year [2024] USD 43.92 billion
Forecast Year [2030] USD 81.42 billion
CAGR (%) 10.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Conjugate Vaccine Market

The Conjugate Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of infectious diseases and immunosuppression
    • Rising adoption of cancer therapeutic vaccines
    • Rising number programs to promote vaccination by WHO
  • Market Restraints
    • Low accessibility to vaccines in remote areas
  • Market Opportunities
    • Government initiatives spreading awareness about infectious diseases
    • Advancement in technology for producing novel conjugate vaccines
  • Market Challenges
    • Complexity of production procedure of conjugate vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Conjugate Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Conjugate Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Conjugate Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Conjugate Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Conjugate Vaccine Market

A detailed market share analysis in the Conjugate Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Conjugate Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Conjugate Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Conjugate Vaccine Market

A strategic analysis of the Conjugate Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Conjugate Vaccine Market, highlighting leading vendors and their innovative profiles. These include Bavarian Nordic, Bharat Biotech Ltd., Bio-Med Limited, Biological E. Limited, Biological E. Ltd, CSL Limited, GlaxoSmithKline, plc., Merck and Company, Novartis AG, Nuron Biotech Inc., Pfizer, Inc., Sanofi Pasteur U.S., LLC, Serum Institute of India Pvt. Ltd., Taj Pharmaceuticals Limited, and Vaxcyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Conjugate Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Monovalent and Multivalent.
  • Based on Indication, market is studied across Diphtheria & Pertussis, Influenza, Meningococcal, and Pneumococcal.
  • Based on Pathogen Type, market is studied across Bacterial Conjugate Vaccine, Combination Conjugate Vaccine, and Viral Conjugate Vaccine.
  • Based on End-User, market is studied across Adults and Children.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of infectious diseases and immunosuppression
      • 5.1.1.2. Rising adoption of cancer therapeutic vaccines
      • 5.1.1.3. Rising number programs to promote vaccination by WHO
    • 5.1.2. Restraints
      • 5.1.2.1. Low accessibility to vaccines in remote areas
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives spreading awareness about infectious diseases
      • 5.1.3.2. Advancement in technology for producing novel conjugate vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of production procedure of conjugate vaccine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Conjugate Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Monovalent
  • 6.3. Multivalent

7. Conjugate Vaccine Market, by Indication

  • 7.1. Introduction
  • 7.2. Diphtheria & Pertussis
  • 7.3. Influenza
  • 7.4. Meningococcal
  • 7.5. Pneumococcal

8. Conjugate Vaccine Market, by Pathogen Type

  • 8.1. Introduction
  • 8.2. Bacterial Conjugate Vaccine
  • 8.3. Combination Conjugate Vaccine
  • 8.4. Viral Conjugate Vaccine

9. Conjugate Vaccine Market, by End-User

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Children

10. Americas Conjugate Vaccine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Conjugate Vaccine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Conjugate Vaccine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bavarian Nordic
  • 2. Bharat Biotech Ltd.
  • 3. Bio-Med Limited
  • 4. Biological E. Limited
  • 5. Biological E. Ltd
  • 6. CSL Limited
  • 7. GlaxoSmithKline, plc.
  • 8. Merck and Company
  • 9. Novartis AG
  • 10. Nuron Biotech Inc.
  • 11. Pfizer, Inc.
  • 12. Sanofi Pasteur U.S., LLC
  • 13. Serum Institute of India Pvt. Ltd.
  • 14. Taj Pharmaceuticals Limited
  • 15. Vaxcyte, Inc.

LIST OF FIGURES

  • FIGURE 1. CONJUGATE VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. CONJUGATE VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONJUGATE VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CONJUGATE VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA & PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023